Nektar Therapeutics (NKTR) Other financing activities (2012 - 2026)

Nektar Therapeutics' Other financing activities history runs 15 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 57828.57% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 127.0% increase from a year earlier, with the FY2024 full-year figure at $15.0 million, changed N/A from the prior year.
• Other financing activities climbed to $4.1 million in Q1 2026 per NKTR's latest filing, from -$456000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $30.0 million in Q1 2024 and bottomed at -$30.0 million in Q2 2024.
• The 5-year median for Other financing activities is $18000.0 (2023), against an average of $1.3 million.
• Biggest YoY gain for Other financing activities was 83238.89% in 2024; the steepest drop was 166644.44% in 2024.
• Year by year, Other financing activities stood at $8000.0 in 2022, then tumbled by 325.0% to -$18000.0 in 2023, then soared by 83238.89% to $15.0 million in 2024, then plunged by 103.05% to -$456000.0 in 2025, then soared by 989.25% to $4.1 million in 2026.
• Per Business Quant, the three latest NKTR Other financing activities figures stand at $4.1 million (Q1 2026), -$456000.0 (Q4 2025), and $456000.0 (Q3 2025).